Oloromosib with Immunotherapy as First Treatment for KRAS G12C Lung Cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer that is advanced (stage IIIB, IIIC, or IV) and cannot be cured with surgery or radiation.
- Your tumor must have a specific change called KRAS G12C mutation and its PD-L1 level must be known.
- You cannot have had any prior treatment for advanced lung cancer (except one standard cycle if urgently needed).
- You must be in good enough health to be up and about (ECOG 0 or 1) and able to swallow pills.
- You must not have other treatable genetic changes like EGFR, ALK, or BRAF.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy (olomorasib) combined with standard treatments for people with a specific type of non-small cell lung cancer that has a KRAS G12C mutation. Depending on the stage of your cancer, you may receive it before or after surgery, or along with chemotherapy and radiation.
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
This trial tests a new targeted pill (HS-10370) combined with standard chemotherapy, with or without an immunotherapy drug (adebrelimab), versus another standard treatment (tislelizumab plus chemotherapy) as the first treatment for advanced lung cancer with a KRAS G12C mutation. The goal is to see if the new combination works better and is safe.
This trial tests a new combination of two targeted drugs (amivantamab and olomorasib) for people with advanced lung cancer that has a specific KRAS G12C mutation. It's for those whose cancer has grown despite prior chemotherapy and immunotherapy.
This trial is testing an oral medication called olomorasib for people with advanced colorectal cancer that has a specific gene change (KRAS G12C). It may be a good option if you have not yet had treatment for cancer that has spread.
This trial tests two new drugs together (sosimerasib and IN10018) as a first treatment for people with a specific type of lung cancer that has the KRAS G12C gene change. The goal is to see if the combination works better than standard therapy.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.